Evidence map›Paper›PMID 37299543›Full record

ReviewNutrients2023

Gut Microbiota Modulation of Short Bowel Syndrome and the Gut-Brain Axis.

Jasmine Carter, Jeffery Bettag, Sylvia Morfin, Chandrashekhara Manithody, Aakash Nagarapu, Aditya Jain, Hala Nazzal, Sai Prem, Meghan Unes, Matthew McHale and 9 more

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Jasmine CarterDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.ORCID 0000-0001-7215-3485
Jeffery BettagDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.ORCID 0000-0003-2712-9499
Sylvia MorfinDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.
Chandrashekhara ManithodyDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.
Aakash NagarapuDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.
Aditya JainDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.
Hala NazzalDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.
Sai PremDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.
Meghan UnesDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.
Matthew McHaleDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.
Chien-Jung LinDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.
Chelsea HutchinsonDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.
Grace TrelloDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.
Arti JainDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.
Edward PortzDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.
Arun VermaDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.ORCID 0000-0001-9374-4823
Marzena Swiderska-SynDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.
Daniel GoldenbergDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.
Kento KurashimaDepartment of Pediatrics, Saint Louis University, Saint Louis, MO 63104, USA.ORCID 0000-0002-3614-2559
Saint Louis University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Short bowel syndrome (SBS) is a condition that results from a reduction in the length of the intestine or its functional capacity. SBS patients can have significant side effects and complications, the etiology of which remains ill-defined. Thus, facilitating intestinal adaptation in SBS remains a major research focus. Emerging data supports the role of the gut microbiome in modulating disease progression. There has been ongoing debate on defining a "healthy" gut microbiome, which has led to many studies analyzing the bacterial composition and shifts that occur in gastrointestinal disease states such as SBS and the resulting systemic effects. In SBS, it has also been found that microbial shifts are highly variable and dependent on many factors, including the anatomical location of bowel resection, length, and structure of the remnant bowel, as well as associated small intestinal bacterial overgrowth (SIBO). Recent data also notes a bidirectional communication that occurs between enteric and central nervous systems called the gut-brain axis (GBA), which is regulated by the gut microbes. Ultimately, the role of the microbiome in disease states such as SBS have many clinical implications and warrant further investigation. The focus of this review is to characterize the role of the gut microbiota in short bowel syndrome and its impact on the GBA, as well as the therapeutic potential of altering the microbiome.

Indexed as

Gastrointestinal MicrobiomeShort Bowel SyndromeBacteriaBrain-Gut AxisDysbiosisHumansIntestine, Smalldysbiosisgastrointestinal diseasegut-brain axisgut microbiomegut microbiotaprobioticsshort bowel syndrome

Identifiers

PMID37299543
PMCPMC10255811
OpenAlexW4378983194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.